专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20190216948A1 MODULATION OF FLUID INTAKE 审中-公开
公开(公告)号：US20190216948A1
公开(公告)日：2019-07-18
申请号：US16245801
申请日：2019-01-11
申请人： California Institute of Technology
发明人： Yuki Oka , Vineet Augustine
IPC分类号： A61K48/00 , A61P43/00 , A61K31/5513 , C12N7/00 , C12N15/86 , A61K38/17 , A61P13/12
CPC分类号： A61K48/005 , A61K31/5513 , A61K38/1787 , A61P13/12 , A61P43/00 , C12N7/00 , C12N15/86 , C12Y114/13039
摘要： In some embodiments, methods of stimulating fluid intake in a subject in need thereof are described. The methods can comprise stimulating a nitric oxide synthase (nNOS)-positive neuron of the median preoptic nucleus (MnPO). In some embodiments, methods of inhibiting fluid intake in a subject in need thereof are described. The methods can comprise inhibiting stimulation of an nNOS-positive neuron of the MnPO.

2. 发明申请

US20170266319A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH SPINAL CORD INJURY 审中-公开
公开(公告)号：US20170266319A1
公开(公告)日：2017-09-21
申请号：US15464471
申请日：2017-03-21
申请人： Children's Hospital Medical Center
发明人： Masaki Ueno , Yutaka Yoshida , Phillip G. Popovich
IPC分类号： A61K48/00 , A61J1/18 , C12N7/00 , A61K38/17 , A61K31/498 , A61K31/662
CPC分类号： A61K38/1787 , A61K31/498 , A61K31/662 , C12N2750/14143
摘要： In one aspect, a method of treating a condition associated with spinal cord injury is disclosed, wherein an agent that inhibits excitatory neurons and/or activates inhibitory interneurons may be administered to an individual in need thereof. Articles of manufacture and kits related to the disclosed methods are also disclosed.

3. 发明申请

US20170266222A1 MODULATION OF CHRFAM7A FOR ANTI-INFLAMMATORY THERAPIES 审中-公开
公开(公告)号：US20170266222A1
公开(公告)日：2017-09-21
申请号：US15425595
申请日：2017-02-06
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： Andrew Baird , Raul Coimbra , Todd Costantini , Brian Eliceiri
IPC分类号： A61K31/739 , A61K38/17 , C07K16/44
CPC分类号： A61K31/739 , A61K31/7088 , A61K38/1787 , A61K45/06 , A61K2300/00
摘要： The invention provides a pharmaceutical composition and methods of use thereof, for anti-inflammatory treatment, by altering expression and/or activity of CHRFAM7A, in leukocytes, as well as in epithelial cells.

4. 发明授权

US09629892B2 Treatment of penetrative injury to the brain 有权
公开(公告)号：US09629892B2
公开(公告)日：2017-04-25
申请号：US13816663
申请日：2011-08-12
申请人： Michael Tymianski , Peter S. Lu , Jonathan David Garman
发明人： Michael Tymianski , Peter S. Lu , Jonathan David Garman
IPC分类号： A61K38/07 , A61K38/08 , C07K7/06 , A61K47/48 , G01N33/573 , G01N33/68 , C12N9/02 , A61K38/17
CPC分类号： A61K38/07 , A61K38/08 , A61K38/1709 , A61K38/1787 , A61K47/645 , C07K7/06 , C07K2319/10 , C12N9/0075 , C12Y114/13039 , G01N33/573 , G01N33/6872 , G01N2333/70571 , G01N2333/90254 , G01N2500/02
摘要： The invention provides methods of treatment or prophylaxis of damaging effects of penetrative injury to the brain or other part of the central nervous system. The methods are based in part on results in a rodent model of penetrative ballistic injury showing that an inhibitor of PDF-95 NMDAR interaction is effective in inhibiting neurological deficits resulting from such injury. The methods are useful for treating subjects having or at risk of penetrative brain injury, including subjects who have been shot in the head or at risk of such injury (e.g., military or law enforcement personnel).

5. 发明申请

US20140228299A1 PROPHYLACTIC AND THERAPEUTIC AGENT FOR NEUROLOGICAL DISEASES USING LIPOPROTEINS AND PROPHYLACTIC AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES 审中-公开
标题翻译：使用脂蛋白和神经病学和神经病学治疗方法治疗神经病变的预防和治疗药物
公开(公告)号：US20140228299A1
公开(公告)日：2014-08-14
申请号：US14346002
申请日：2012-09-19
申请人： National University Corporation Tokyo Medical and Dental University , National University Corporation Kumamoto University
发明人： Hideki Hayashi
IPC分类号： A61K38/17
CPC分类号： A61K38/1709 , A61K38/1787 , A61K38/45 , A61K38/465
摘要： The present invention provides an agent for neurological disease, the agent comprising lipoprotein containing apolipoprotein E as the active substance thereof, in which a neuroprotective system via activation of neuroprotective molecules and/or the inactivation of neurodegeneration-inducing molecules, mediated by lipoprotein receptors, may work as a mechanism, and a prophylactic and therapeutic method for neurological diseases. The lipoproteins containing apolipoprotein E and/or neuroprotective system through, as the action mechanism, the activation of neuroprotective molecules and the inactivation of neurodegeneration-inducing molecules that are mediated by lipoprotein receptors have prophylactic and therapeutic effects of, including, inhibiting nerve cell apoptosis, on neurological disease such as various neurodegenerative diseases accompanied by nerve cell apoptosis as the essential condition. The invention provides the agent comprising apolipoprotein E-containing lipoproteins and/or having an action mechanism through the activation of neuroprotective molecules and the inactivation of neurodegeneration-inducing molecules that are mediated by lipoprotein receptors.
摘要翻译：本发明提供了一种用于神经系统疾病的药剂，其包含含有脂蛋白的载脂蛋白E作为其活性物质，其中通过神经保护分子的激活和/或由脂蛋白受体介导的神经变性诱导分子的失活的神经保护系统可以作为机制，以及神经系统疾病的预防和治疗方法。含有载脂蛋白E和/或神经保护系统的脂蛋白通过作为动作机制的神经保护分子的活化和由脂蛋白受体介导的神经变性诱导分子的失活具有预防和治疗作用，包括抑制神经细胞凋亡，神经系统疾病如各种神经退行性疾病伴随神经细胞凋亡作为基本条件。本发明提供包含载脂蛋白E的脂蛋白和/或具有通过激活神经保护分子的作用机制和由脂蛋白受体介导的神经变性诱导分子的失活的药剂。

6. 发明授权

US07691590B2 Reducing myelin-mediated inhibition of axon regeneration 失效
标题翻译：减少髓鞘介导的轴突再生抑制
公开(公告)号：US07691590B2
公开(公告)日：2010-04-06
申请号：US11958632
申请日：2007-12-18
申请人： Zhigang He , Kevin C. Wang , Vuk Koprivica , Jieun A. Kim
发明人： Zhigang He , Kevin C. Wang , Vuk Koprivica , Jieun A. Kim
IPC分类号： G01N33/53 , G01N33/68 , G01N33/58 , G01N33/577
CPC分类号： C07K16/18 , A61K38/1787 , A61K2039/505 , C07K2317/55 , G01N33/6896 , G01N2500/02
摘要： Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.
摘要翻译：少突胶质细胞 - 髓磷脂糖蛋白（OMgp）特异性结合剂用于减少OMgp介导的轴突生长抑制。轴突和OMgp的混合物和Nogo受体（NgR）和OMgp的混合物用于药物筛选中以表征药剂作为NgR与OMgp的结合并促进轴突再生。

7. 发明申请

US20090036376A1 Treatment for Anxiety 有权
标题翻译：焦虑治疗
公开(公告)号：US20090036376A1
公开(公告)日：2009-02-05
申请号：US12165983
申请日：2008-07-01
申请人： Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
发明人： Andrew Tasker , Tracy Doucette , Michael Tymianski , Kenneth Mendoza , Michael P. Belmares , David Garman , Peter S. Lu
IPC分类号： A61K38/10 , A61K38/08 , A61K38/16 , A61P25/22
CPC分类号： A61K38/1787 , A61K38/07
摘要： The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.
摘要翻译：本发明提供了治疗或预防患有或有发生焦虑症状的患者的方法，其中向患者施用抑制PSD95与NMDA受体的特异性结合的药剂的有效方案。

8. 发明申请

US20070149483A1 Methods and compounds for modulating triglyceride and vldl secretion 审中-公开
标题翻译：调节甘油三酯和vldl分泌的方法和化合物
公开(公告)号：US20070149483A1
公开(公告)日：2007-06-28
申请号：US10582288
申请日：2004-12-13
申请人： James Jamieson , Gro Thorne-Tjomsland , Zemin Yao , Andrea Marat , Khai Tran
发明人： James Jamieson , Gro Thorne-Tjomsland , Zemin Yao , Andrea Marat , Khai Tran
IPC分类号： A61K31/685 , G01N33/567
CPC分类号： G01N33/92 , A61K38/1709 , A61K38/177 , A61K38/1787 , A61K38/45 , G01N33/5076 , G01N2800/044
摘要： The invention provides uses of autophagocytosis inducing compounds for reducing serum levels of triglycerides and VLDL and the preparation of medicaments. The invention also provides the use of autophagocytosis inducing compounds for treating hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia, atherosclerosis, arteriosclerosis, peripheral artery disease, coronary artery disease, congestive heart failure, myocardial ischemia, myocardial infarction, ischemic stroke, hemorrhagic stroke, or diabetes, insulin resistance, hemodialysis, glycogen storage disease type I, polycystic ovary syndrome, combination thereof. The invention further provides methods of identifying compounds which modulate autophagocytosis.
摘要翻译：本发明提供了诱导自噬作用的化合物用于降低甘油三酸酯和VLDL的血清水平以及制备药物的用途。本发明还提供了使用自噬作用诱导化合物治疗高甘油三酯血症，高脂血症，高胆固醇血症，高脂蛋白血症，动脉粥样硬化，动脉硬化，外周动脉疾病，冠状动脉疾病，充血性心力衰竭，心肌缺血，心肌梗塞，缺血性卒中，出血性卒中或糖尿病，胰岛素抵抗，血液透析，I型糖原贮积病，多囊卵巢综合征，其组合。本发明还提供鉴定调节自噬作用的化合物的方法。

9. 发明授权

US07235236B2 Polynucleotide encoding human adenylylcyclase VI and uses thereof for enhancing cardiac function 有权
标题翻译：编码人腺苷酸环化酶VI的多核苷酸及其用于增强心脏功能的用途
公开(公告)号：US07235236B2
公开(公告)日：2007-06-26
申请号：US10942072
申请日：2004-09-14
申请人： H. Kirk Hammond , Paul A. Insel , Peipei Ping , Steven R. Post , Meihua Gao
发明人： H. Kirk Hammond , Paul A. Insel , Peipei Ping , Steven R. Post , Meihua Gao
IPC分类号： A01N63/00 , A61K31/70 , C07H21/02
CPC分类号： C12N9/1205 , A01K2217/05 , A61K38/00 , A61K38/1787 , A61K48/00 , A61K48/0058 , A61K48/0075 , C12N9/88 , C12N15/86 , C12N2710/10343 , C12N2750/14143 , C12N2799/025 , C12N2830/42
摘要： The present invention relates to polynucleotides encoding human adenylylcyclase VI and uses thereof for enhancing cardiac function. The present invention can thus be used in the treatment of heart disease, especially congestive heart failure.
摘要翻译：本发明涉及编码人腺苷酸环化酶VI的多核苷酸及其用于增强心脏功能的用途。因此，本发明可用于治疗心脏病，特别是充血性心力衰竭。

10. 发明申请

US20040192625A1 Adrenergic receptor overexpression in airway tissues for the treatment of airway obstructive diseases 审中-公开
标题翻译：气道组织中的肾上腺素受体过表达用于治疗气道阻塞性疾病
公开(公告)号：US20040192625A1
公开(公告)日：2004-09-30
申请号：US10221332
申请日：2002-12-18
发明人： Stephen Bryant Liggett
IPC分类号： A61K048/00 , C12N015/85
CPC分类号： A61K38/1787 , A61K48/00
摘要： The present invention provides methods to protect a subject from a respiratory disorder involving an airway obstructive disease such as asthma or chronic obstructive pulmonary disease. Provided are methods to protect a subject from an airway obstructive disease using gene therapy. null2-adrenergic receptors (null2AR) act to relax airway smooth muscle and can serve to counteract hyperresponsiveness. Methods are provided for supplying null2AR function to cells of the lung and airway, such as smooth muscle and epithelial cells, by null2AR gene therapy. The null2AR gene, a modified null2AR gene, or a part of the gene may be introduced into the cell in a vector such that the gene remains extrachromosomal or may be integrated into the subjects chromosomal DNA for expression. These methods provide for administering to a subject in need of such treatment a therapeutically effective amount of a null2AR gene, or pharmaceutically acceptable composition thereof, for overexpressing the null2AR gene. Such methods of expressing the administered null2AR gene in the lungs and airway provide for: (1) preventing or alleving bronchial hyperresponsiveness; (2) preventing or alleving of an airway obstructive disease, e.g., bronchial hyperreactivity, airway hyperresponsiveness, asthma or chronic obstructive pulmonary disorder (nullCOPDnull); (3) reducing the airway resistance response to inhaled natural or synthetic bronchoconstrictors or allergens or to exercise; and (4) enhancing responsiveness (relaxation) of airway tissues to null-agonists.
摘要翻译：本发明提供了保护受试者免受涉及气道阻塞性疾病如哮喘或慢性阻塞性肺病的呼吸系统疾病的方法。提供了使用基因治疗来保护受试者免受气道阻塞性疾病的方法。 β2-肾上腺素能受体（β2AR）起着松弛气道平滑肌的作用，可以抵消高反应性。提供了通过β2AR基因治疗将β2AR功能提供给肺和气道细胞如平滑肌和上皮细胞的方法。可以将β2AR基因，修饰的β2AR基因或该基因的一部分引入载体中的细胞中，使得该基因保持染色体外或可以整合入受体染色体DNA进行表达。这些方法提供了对需要这种治疗的受试者施用用于过表达β2AR基因的治疗有效量的β2AR基因或其药学上可接受的组合物。在肺和气道中表达给予的β2AR基因的这种方法规定：（1）预防或反应支气管高反应性; （2）预防或调节气道阻塞性疾病，例如支气管高反应性，气道高反应性，哮喘或慢性阻塞性肺病（“COPD”）; （3）降低吸入天然或合成支气管收缩剂或过敏原或运动的气道阻力反应; 和（4）增强气道组织对β-激动剂的反应性（松弛）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式